Physician profile
Kari Williams
NPI 1467418095
$11,498.99
in general payments reported to CMS, 2019-2025
33 companies · $2,869 in 2025
The $2,869 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,177 · 2022: $761 · 2023: $2,583 · 2024: $3,109 · 2025: $2,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,527 · Education: $33.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,527.33 |
| Education | $33.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,607.62 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,749.12 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,197.28 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $912.83 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Aimmune Therapeutics, INC. | $397.73 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $396.05 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $375.18 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $355.42 | 2022-2025 | Dupixent |
| Pfizer INC. | $305.10 | 2021-2025 | |
| Redhill Biopharma INC. | $260.76 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Merck Sharp & Dohme LLC | $236.62 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $229.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $219.37 | 2021-2025 | Linzess |
| Nestle Healthcare Nutrition INC. | $207.90 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $174.04 | 2024-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $109.99 | 2022 | |
| Evoke Pharma, INC. | $102.72 | 2021-2024 | Gimoti |
| Novo Nordisk INC | $83.35 | 2023-2025 | Wegovy |
| Qol Medical, LLC | $65.95 | 2022-2025 | Sucraid |
| Daiichi Sankyo INC. | $65.91 | 2023-2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $55.02 | 2024 | Bylvay, Iqirvo |
| Ferring Pharmaceuticals INC. | $53.93 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $42.87 | 2024 | Idacio |
| Celgene Corporation | $41.71 | 2021 | |
| Intra-Sana Laboratories | $39.40 | 2022-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lilly USA, LLC | $38.27 | 2024-2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $34.13 | 2025 | Givlaari |
| Amgen INC. | $33.46 | 2022-2023 | Amjevita, Avsola |
| Celltrion USA INC. | $33.25 | 2023-2024 | Zymfentra, Yuflyma |
| Medtronic, INC. | $28.09 | 2023-2024 | Interstim, Gi Genius |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.84 | 2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $15.91 | 2021 | |
| Organon LLC | $5.80 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.